Dimethyl fumarate (Tecfidera) vs Diroximel fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline
Dimethyl fumarate (Tecfidera)
Marketed by Biogen
NCT00451451 · Phase 3 · completed
This was a large (n=1417), randomized, double-blind, placebo-controlled Phase 3 trial with a hard clinical primary endpoint (annualized relapse rate, independently adjudicated). Both BG00012 dosing arms showed clearly separated confidence intervals from placebo on this primary endpoint (0.224 and 0.198 relapses/year vs 0.401 for placebo), indicating the drug met its primary comparison in the favorable direction, satisfying all the elements of well-designed, positive Phase 3 evidence.
Reported efficacy
Annualized Relapse Rate (2 years): Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. (met)
Result source: NCT00451451
Diroximel fumarate · Vumerity
Marketed by Biogen and partners
NCT05083923 · Phase 3 · completed
The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only.
Next expected readout: July 2034 · NCT07483632 (registry estimate)
Reported efficacy
Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B (End of treatment (up to Week 6) for both Parts A and B): Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. (met)
Result source: NCT03093324
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dimethyl fumarate (Tecfidera) | Diroximel fumarate |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.4−0.2 vs placeboNCT004514515 other results
| —Trial running · NCT07483632 |
| Free of 3-month confirmed disability progression (%) | —Not reported | —Trial running · NCT07483632 |
| New or enlarging T2 lesions | —Not reported | —Trial running · NCT07483632 |
Annualised relapse rate
- Dimethyl fumarate (Tecfidera)
- 0.2 vs 0.4−0.2 vs placeboNCT00451451
5 other results
- 0.2 vs 0.4 NCT00451451
- 0.2 vs 0.4 NCT00420212
- 0.2 vs 0.4 NCT00420212
- 0.2 vs 0.5 NCT02283853
- 0.3 vs 0.6 NCT02283853
- Diroximel fumarate
- —Trial running · NCT07483632
Free of 3-month confirmed disability progression (%)
- Dimethyl fumarate (Tecfidera)
- —Not reported
- Diroximel fumarate
- —Trial running · NCT07483632
New or enlarging T2 lesions
- Dimethyl fumarate (Tecfidera)
- —Not reported
- Diroximel fumarate
- —Trial running · NCT07483632
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Dimethyl fumarate (Tecfidera): 6 of 6 rows · Diroximel fumarate: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dimethyl fumarate (Tecfidera) | Diroximel fumarate |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.141 per yeara,b,c NCT02283853 · Phase 3 · registry result, not featured evidence | 0.14 per year @ 96wkd,a,b,c NCT02634307 · Phase 3 · monotherapy show 2 more doses0.11 per year @ 96wk NCT02634307 · Phase 3 · monotherapy 0.13 per year @ 96wk NCT02634307 · Phase 3 · monotherapy |
| EDSS absolute change · score No placebo or comparator arm | -0.11 score @ 336wka,b,e NCT02283853 · Phase 3 · registry result, not featured evidence | 0.07 score @ 96wkd,a,b,e NCT02634307 · Phase 3 · monotherapy show 2 more doses-0.01 score @ 96wk NCT02634307 · Phase 3 · monotherapy 0.03 score @ 96wk NCT02634307 · Phase 3 · monotherapy |
| Dropout rate | 20.9%240 mg 3 times dailyf NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results20.9%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 23.1%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 23.2%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 55.8%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 56.8%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 14.8% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 21.5%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence —Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence — NCT02555215 · Phase 3 · registry result, not featured evidence 27.5% NCT02525874 · Phase 3 · registry result, not featured evidence 9.1% NCT02410200 · Phase 2 · registry result, not featured evidence —Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination —Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination | 9.6%Cohort 1: Japanese Participantsg NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results20%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 21.1%De Novo NCT02634307 · Phase 3 · monotherapy 29.7%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 27.1%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 3.5% NCT03093324 · Phase 3 · monotherapy |
| Discontinued due to AEs | 7.5%240 mg 3 times dailyf NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results5.8%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.7%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 9.8%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 13%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 14.3%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 10.1% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 6.3%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence —Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence — NCT02555215 · Phase 3 · registry result, not featured evidence 7.8% NCT02525874 · Phase 3 · registry result, not featured evidence 9.1% NCT02410200 · Phase 2 · registry result, not featured evidence —Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination —Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination | 3.8%Cohort 1: Japanese Participantsg NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results0%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.4%De Novo NCT02634307 · Phase 3 · monotherapy 10%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 6.2%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 1.6% NCT03093324 · Phase 3 · monotherapy |
| Serious AEs | 15.7%240 mg 3 times dailyf NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results17%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 15.6%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 18%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 32.1%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 31.3%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 3% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 23.1%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence 14%Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence 10% NCT02555215 · Phase 3 · registry result, not featured evidence 11.9% NCT02525874 · Phase 3 · registry result, not featured evidence 22.7% NCT02410200 · Phase 2 · registry result, not featured evidence 2.1%Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination 3.5%Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination | 11.5%Cohort 1: Japanese Participantsg NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results12%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 11.6%De Novo NCT02634307 · Phase 3 · monotherapy 12.1%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 11.1%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 1.6% NCT03093324 · Phase 3 · monotherapy |
| Most frequent reported AEs | 240 mg 3 times dailyf flushing 24.1% (placebo 3.6%) multiple sclerosis relapse 23.5% (placebo 40.5%) nasopharyngitis 18.3% (placebo 16%) NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 12 more results240 mg twice daily flushing 30.6% (placebo 3.6%) multiple sclerosis relapse 29% (placebo 40.5%) nasopharyngitis 17.3% (placebo 16%) NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg TID flushing 31.7% (placebo 4.9%) nasopharyngitis 26.2% (placebo 24.8%) multiple sclerosis relapse 25.7% (placebo 44.4%) NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg BID flushing 37.3% (placebo 4.9%) multiple sclerosis relapse 26.6% (placebo 44.4%) nasopharyngitis 26.3% (placebo 24.8%) NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg twice daily multiple sclerosis relapse 37.3% nasopharyngitis 25.3% urinary tract infection 22.6% NCT00835770 · Phase 3 · monotherapy 240 mg three times daily multiple sclerosis relapse 38.6% nasopharyngitis 26% flushing 19% NCT00835770 · Phase 3 · monotherapy abdominal pain 41% flushing 38.5% multiple sclerosis relapse 29.5% NCT02283853 · Phase 3 · registry result, not featured evidence multiple sclerosis relapse 26.3% headache 22.8% covid-19 19.3% NCT02283853 · Phase 3 · registry result, not featured evidence flushing 25% multiple sclerosis relapse 20% abdominal pain 15% NCT02555215 · Phase 3 · registry result, not featured evidence flushing 45.9% multiple sclerosis relapse 18.8% nasopharyngitis 15.1% NCT02525874 · Phase 3 · registry result, not featured evidence flushing 45.5% multiple sclerosis relapse 31.8% abdominal pain 27.3% NCT02410200 · Phase 2 · registry result, not featured evidence flushing 53.2% alanine aminotransferase increased 14.9% diarrhoea 14.9% NCT01156311 · Phase 2 · registry result, not featured evidence · combination flushing 42.1% diarrhoea 31.6% abdominal pain 21.1% NCT01156311 · Phase 2 · registry result, not featured evidence · combination | g diarrhoea 36.5% flushing 32.7% nasopharyngitis 21.2% NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more resultsupper respiratory tract infection 36% flushing 18% lymphocyte count decreased 16% NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 flushing 38.1% multiple sclerosis relapse 15.7% nasopharyngitis 14.5% NCT02634307 · Phase 3 · monotherapy multiple sclerosis relapse 19.7% upper respiratory tract infection 17.6% lymphopenia 14.6% NCT02634307 · Phase 3 · monotherapy multiple sclerosis relapse 19.6% lymphopenia 16.9% upper respiratory tract infection 15.6% NCT02634307 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 336 weeks versus 96 weeks.
- fPopulation comparability has not been reviewed for 10 of these studies.
- gPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dimethyl fumarate (Tecfidera)
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 17 further endpoints in the CSV export.
Diroximel fumarate
show 2 more results
show 23 more results
show 11 more results
show 11 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dimethyl fumarate (Tecfidera)'s landscape · Diroximel fumarate's landscape